Homology Medicines (NASDAQ:FIXX) Announces Earnings Results

Homology Medicines (NASDAQ:FIXX) issued its quarterly earnings data on Thursday. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.06), Bloomberg Earnings reports. The firm had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $1.00 million. Homology Medicines had a negative return on equity of 43.28% and a negative net margin of 3,232.67%.

Shares of FIXX stock traded up $0.01 during mid-day trading on Friday, hitting $15.80. 119,738 shares of the stock were exchanged, compared to its average volume of 360,374. The firm’s fifty day moving average price is $18.84. The company has a market capitalization of $688.66 million, a PE ratio of -7.90 and a beta of 0.15. Homology Medicines has a 12-month low of $15.06 and a 12-month high of $31.80.

In related news, insider Albert Seymour sold 9,300 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.90, for a total transaction of $185,070.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Arthur Tzianabos sold 12,500 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.86, for a total value of $248,250.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 686,600 shares of company stock worth $14,606,534. Corporate insiders own 33.40% of the company’s stock.

Several brokerages have issued reports on FIXX. Canaccord Genuity set a $37.00 price objective on Homology Medicines and gave the stock a “buy” rating in a report on Friday, July 26th. HC Wainwright set a $36.00 price objective on Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, June 11th. ValuEngine lowered Homology Medicines from a “buy” rating to a “hold” rating in a report on Friday, April 19th. Finally, Zacks Investment Research raised Homology Medicines from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Homology Medicines presently has a consensus rating of “Buy” and an average target price of $29.10.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Further Reading: Investing strategies using the yield curve

Earnings History for Homology Medicines (NASDAQ:FIXX)

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.